Tobira Therapeutics

Frazier hits $419M for early-stage biotech investments

California investment firm Frazier Healthcare Partners has gone over its hard cap target of $400 million as it looks to inject cash into early life science work.

Ben Adams Nov 1, 2017 5:00am

Allergan buys another NASH biotech in M&A spree

Sep 21, 2016 6:22am

Reverse mergers take on 2016, as IPOs ready for 2017 comeback

Sep 20, 2016 12:22pm

Acquisitive Allergan buys micro-cap NASH biotech Tobira months after trial miss

Sep 20, 2016 8:36am

Small cap Tobira tanks on NASH trial miss

Jul 25, 2016 9:37am

Tobira and Korea's Dong-A ST sign $80M diabetes/NASH deal

Apr 11, 2016 10:47am